

## SUBOXONE/SUBUTEX OPIOID DETOXIFICATION PRIOR AUTHORIZATION REQUEST FORM

This completed form may be FAXED TO 1-866-399-0929\* Requests for prior authorization (PA) requests must include member name, ID#, and drug name. *Incomplete forms will delay processing.*

A 72-hour supply of medication may be requested by phoning 1-800-460-8988.

Request may be mailed to: US Script PA Dept. / 2425 West Shaw Avenue / Fresno, CA 93711

US Script will respond via fax or phone within 24 hours of receipt of all necessary information, except during weekends and holidays.

For immediate response on weekends and holidays, NurseWise will answer your call.

<b>I. Provider Information</b>		<b>II. Member Information</b>	
Prescriber name (print):		Member Name:	
Office Contact Name:		ID#:	
Fax:		Date of Birth:	
Phone:		Medication allergies:	
<b>III General Information – (Please complete for both Suboxone and Subutex requests).</b>			
Drug name and strength – Circle One <b>Suboxone</b> <b>Subutex</b>		Dose:	Dosage Interval (sig):
		Qty per Day:	
Diagnosis relevant to this request/ICD-9 code: <span style="margin-left: 150px;">Opioid Dependence – 304.0</span>		Data 2000 Waiver ID (“X” DEA Number):	
Expected length of therapy:			
<b>Documentation that outlines the clinical evaluation and the opioid dependence treatment plan <u>must be provided with the initial request</u> for Suboxone that includes the proposed titration schedule from starting dose to drug free status.</b>			
Is the Member Pregnant? (Circle One):		If Yes, please state the estimated delivery date:	
Is the patient allergic to Naloxone? (Circle One):			
<b>If “No” was not selected for one of the questions above and <u>Subutex</u> is being requested, please provide the clinical rationale for prescribing <u>Subutex</u> instead of Suboxone in the space below:</b>			
<b>IV: Renewal Information - (Please complete ONLY for Renewal Requests).</b>			
Please check off all clinical rationale for the renewal of Suboxone/Subutex and provide supportive documentation that supports its clinical necessity:			
<input type="checkbox"/> Consistent use of Suboxone/Subutex since the initial authorization was granted (note: if gaps of therapy are apparent in the pharmacy claims database, an explanation as to why these gaps are present will be required).			
<input type="checkbox"/> Continued participation in drug abuse counseling (attach relevant documentation to confirm such enrollment).			
<input type="checkbox"/> Monthly negative urine tests for opiates since authorization (attach all monthly urine drug screens since the initial authorization was granted).			
<b>V: Approval and Renewal Criteria</b>			
Suboxone® (not Subutex®) can be approved for induction and dose stabilization for a period not to exceed 30 days. An additional 3 month period can be approved based on submission of information verifying continued participation in drug abuse counseling and continued drug monitoring. Subutex® treatment can be approved during pregnancy. Methadone is the therapy of choice for treatment of opioid addiction in pregnancy. Do not use this form for pain management. Prescriber must be certified to prescribe Suboxone and manage opioid dependence and be issued a Data 2000 Waiver ID number (“X” DEA number). Documentation that outlines the clinical evaluation and the opioid dependence treatment plan that includes the proposed titration schedule down to drug free <u>must</u> be provided with the initial request for Suboxone.			
<b>VI. ADDITIONAL PERTINENT CLINICAL INFORMATION / RATIONALE FOR REQUEST:</b>			
Provider Signature:			Date: